January 14, 2022
January 14, 2022 – AbbVie's Rinvoq® (upadacitinib) has been approved to treat moderate to severe atopic dermatitis (AD) in patients at least 12 years old who have refractory disease
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
January 14, 2022
January 14, 2022 – The U.S. FDA has approved Cibinqo® (abrocitinib) to treat moderate to severe atopic dermatitis in adults who have refractory disease not adequately controlled with other
January 13, 2022
January 13, 2022 – RyaltrisTM (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray
has been FDA approved to treat the symptoms of seasonal allergic rhinitis in patients
January 12, 2022
January 12, 2022 – In a drug safety communication, the U.S. FDA has cautioned that dental problems can occur with buprenorphine products that are taken by dissolving them in the mouth
January 11, 2022
January 11, 2022 – The U.S. FDA has announced revisions to the Johnson & Johnson (Janssen) COVID-19
vaccine fact sheets regarding the risk of immune thrombocytopenia (ITP)
January 10, 2022
January 10, 2022 – Quviviq (daridorexant – Idorsia) has received FDA approval to treat adults who have insomnia characterized by difficulties with sleep onset and/or sleep
January 7, 2022
January 7, 2022 – Viona Pharmaceuticals has recalled 33 lots of Metformin Hydrochloride Extended-Release Tablets, USP 750mg, due to N-nitrosodimethylamine (NDMA) amounts
January 7, 2022
January 7, 2022 – The U.S. FDA has updated emergency use authorization for Moderna's COVID-19 vaccine
to shorten the time between the primary vaccination series and receipt